## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA P Form 4 June 11, 20	HARMACEUTIC	CALS INC	2									
FORM	ЛЛ									PPROVA	L	
	UNITED	STATES		RITIES A			IGE	COMMISSION	N OMB Number:	3235-	0287	
Check t if no lor subject Section Form 4 Form 5		NGES IN SECUF	Estimated burden hou	Expires: January 3 200 Estimated average burden hours per response 0								
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type	Responses)											
1. Name and Rasmusser	2. Issuer Name <b>and</b> Ticker or Trading Symbol ACADIA PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer							
			INC [ACAD]					(Check all applicable)				
(Last) 3911 SOR	3. Date of Earliest Transaction (Month/Day/Year) 06/07/2013				Director 10% Owner Officer (give title Other (specify below)							
	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
SAN DIEC	GO, CA 92121							Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	e Securit	ties Ao	cquired, Disposed o	of, or Beneficia	lly Owned	f	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if TransactionAcquired ( Code Disposed o ay/Year) (Instr. 8) (Instr. 3, 4			l (A) or l of (D) 4 and 5) (A) or		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownershi (Instr. 4)	al ip	
Reminder: Pa	port on a separate line	for each a	ass of see	urities bene	ficially ou	med dire	ctly o	r indirectly				
Kenniuer: Ke	port on a separate line	for each cr	ass of sec	unities bene	Perse infor requi	ons who mation red to r ays a ci	o resp conta respo	pond to the colle ained in this form and unless the for tly valid OMB co	i are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)		(Instr.	8)	or Dispos (D)	(Instr. 3, 4,				(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 17.01	06/07/2013		Α		12,500		<u>(1)</u>	06/06/2023	Common stock	12,500

## **Reporting Owners**

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.

(2) The stock options are held by Morgan Management ApS, a Danish corporation in which Mr. Rasmussen has a controlling interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(